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Specific receptors on the surface of mammalian cells actively internalize cell-impermeable ligands by
receptor-mediated endocytosis. To mimic these internalizing receptors, my laboratory is studying artificial cell surface
receptors that comprise N-alkyl derivatives of 3b-cholesterylamine linked to motifs that bind cell-impermeable
ligands. When added to living mammalian cells, these synthetic receptors insert into cellular plasma membranes,
project ligand-binding small molecules or peptides from the cell surface, and enable living cells to internalize targeted
proteins and other cell-impermeable compounds. These artificial receptors mimic their natural counterparts by
rapidly cycling between plasma membranes and intracellular endosomes, associating with proposed cholesterol and
sphingolipid-rich lipid raft membrane microdomains, and delivering ligands to late endosomes/lysosomes. This
“synthetic receptor targeting” strategy is briefly reviewed here and contrasted with other related cellular delivery
systems. Potential applications of artificial cell surface receptors as molecular probes, agents for cellular targeting,
tools for drug delivery, and methods for ligand depletion are discussed. The construction of synthetic receptors as
prosthetic molecules, designed to seamlessly augment the molecular machinery of living cells, represents an exciting
new frontier in the fields of bioorganic chemistry and chemical biology.
Introduction
Mammalian cells sport a vast array of structurally divergent
receptors on their surfaces. Some of these receptors are large
transmembrane proteins over one hundred thousand dalton
in molecular weight that play key roles in cellular signaling
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or nutrient uptake. Other much smaller receptors include
glycolipids, typically less than two thousand dalton, involved in
the cellular processes of endocytosis and adhesion. A defining
feature of these diverse biomolecules is a ligand-binding motif
that projects from the cell surface and engages a specific molecule
in the aqueous environment. These motifs are typically attached
to the cell by either protein alpha helices that span the plasma
membrane or by covalently linked lipids that insert into the outer
leaflet of the membrane’s lipid bilayer. Transmembrane segments
of cell surface proteins often protrude into the cytoplasm and
interact with intracellular proteins. This bridge to the interior of
the cell enables ligands that bind on the cell surface to transmit
signals to effector molecules in the cellular cytoplasm. These
effectors include enzymes involved in cellular signaling and
components of the molecular machinery controlling the ligand
uptake process of endocytosis. Receptor-mediated endocytosis is
a major mechanism by which cells consume nutrients available in
the environment and terminate signals initiated by extracellular
proteins. This process is also exploited by opportunistic proteins
and pathogens to invade living cells.1
The LDL receptor: a prototypical macromolecular
cell surface receptor
One of the most extensively characterized internalizing cell sur-
face receptors is the low-density lipoprotein (LDL) receptor.2–4
As illustrated in Fig. 1, this large single-pass transmembrane
protein specializes in the uptake of cholesterol-laden LDL
particles. By recognizing the Apo-B protein component of
LDL, the LDL receptor enables cells to internalize exogenous
cholesterol, a key building block required for the biosynthesis
of steroid hormones, bile acids, and cellular plasma membranes.
For this reason, the LDL receptor is often overexpressed on
rapidly proliferating cancer cells in demand of high levels of
membrane biosynthesis, providing a target for the selective
delivery of anticancer and tumor imaging agents.5,6 As shown
in Fig. 2, receptor-mediated endocytosis of LDL is initiated by
clustering of receptor/ligand complexes on the cell surface in pits
coated by the intracellular protein clathrin. Clathrin controls theDO
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Fig. 1 Structural depictions of the LDL particle (top) and its cell
surface receptor (bottom). The extracellular domain of the LDL
receptor (shown as the X-ray structure, PDB: 1N7D) binds the Apo-B
protein of LDL to initiate receptor-mediated endocytosis of this ligand.
Fig. 2 Endocytosis of LDL (sphere) mediated by the LDL receptor (R).
Cellular demand for cholesterol results in upregulation of biosynthesis
of the LDL receptor in membranes of the endoplasmic reticulum, and
the receptor is secreted through the Golgi complex to the cell surface.
Binding of the receptor to LDL in the extracellular environment results
in uptake of this ligand by endocytosis, trafficking of LDL to degratory
lysosomes, and recycling of the receptor back to the cell surface.
endocytosis of many cell surface receptors, and this membrane-
associated protein interacts either directly or indirectly with the
intracellular domain of the LDL receptor. Clathrin-coated pits
containing LDL-bound LDL receptors invaginate and pinch
off to form intracellular endocytic vesicles. These internalized
vesicles are acidified by the activation of proton pumps and fuse
in the cytoplasm to form larger acidic (pH ∼ 6) endosomes.
Receptors dissociate from ligands in endosomes, and the free
receptor cycles back to the cell surface, allowing the LDL
receptor to be reused up to several hundred times during
its ∼20 h lifespan. Endosomes containing free LDL fuse
with lysosomes, more acidic (pH ∼ 5) organelles containing
hydrolytic enzymes that liberate needed cholesterol and amino
acid nutrients for delivery into the cytoplasm.2,3
Ganglioside GM1: a small internalizing cell surface
receptor
Despite its small size (molecular weight = 1630 Da), ganglioside
GM1 (Fig. 3) functions similarly as an internalizing cell surface
receptor. This small receptor is targeted by the protein cholera
toxin,7 which penetrates into cells by endocytosis after multi-
valent binding to the glycolipid pentasaccaride headgroup.8–10
However, because ganglioside GM1 is restricted to the outer
leaflet of the plasma membrane, the molecular machinery that
regulates the endocytosis of the cholera toxin differs in certain
respects from that used to internalize LDL. The endocytosis
of the cholera toxin, mediated by GM1, has been proposed to
involve lipid rafts, plasma membrane subdomains enriched in
cholesterol and sphingolipids.11–14 Many proteins covalently or
noncovalently associated with cholesterol, sphingolipids such as
ganglioside GM1, or saturated lipids of cellular membranes,
are thought to associate with lipid rafts.15 These membrane
subdomains have been proposed to segregate and concentrate
membrane proteins, regulate the activation of specific signal
transduction pathways,16 and control the endocytosis of specific
receptors.17 In certain cell lines, particularly those with high ex-
pression levels of ganglioside GM1,18 endocytosis of the cholera
toxin is thought to involve lipid raft-dependent pathways.19
However, in enterocytes and neurons, endocytosis of the cholera
toxin is thought to predominantly involve clathrin.20 Multiple,
simultaneous, mechanisms of endocytosis of this toxin have also
been observed.21,22 Yet, the mechanism that couples recognition
Fig. 3 Structures of the opportunistic ligand cholera toxin (top) and
its small cell surface receptor ganglioside GM1 in a model lipid raft
(bottom). The X-ray structure of the cholera toxin B-subunit is shown
bound to GM1 oligosaccarides (PDB: 3CHB).
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of the glycolipid on the outer leaflet of the membrane to the
clathrin machinery on the inner leaflet remains to be defined.
The bound cholera toxin is initially delivered by GM1 into
endosomes, but this protein bypasses lysosomes, traffics into
the Golgi complex and endoplasmic reticulum, and escapes into
the cytosol, where it functions as a catalytic toxin. Many protein
toxins and viruses exploit receptor-mediated endocytosis involv-
ing lipid rafts or clathrin to access the interior of living cells.23
Due to the efficiency of receptor-mediated endocytosis as a de-
livery mechanism, cell surface receptors involved in this process
have been extensively targeted to enable cellular uptake of poorly
permeable molecules. Ligands of internalizing receptors have
been linked to drugs, molecular probes, and macromolecules to
deliver these conjugates into cells.24 Receptors targeted in this
way include LDL receptors,6 glycosylphosphatidylinositol (GPI)
lipid-anchored folate receptors,25 and transferrin receptors,26
all of which tend to be overexpressed on rapidly proliferating
cells. Low expression of these receptors provides a common
mechanism of resistance to these types of targeted therapeutics.
Artificial cell surface receptors: tools for synthetic
receptor targeting
My laboratory is investigating synthetic compounds designed
to mimic mammalian cell surface receptors. These receptor
mimics are designed to enable receptor-mediated endocytosis
of impermeable ligands that do not bind natural receptors
expressed on cell surfaces. These artificial receptors comprise
the non-natural membrane anchor N-alkyl-3b-cholesterylamine
linked to binding motifs for proteins and other poorly per-
meable compounds. As shown in Fig. 4, we have linked this
membrane anchor to fluorophores (receptors 1, 7, and 8),27,28
the dinitrophenyl hapten (receptor 6),28 biotin (receptor 2),29
and peptides (receptors 3, 4, and 5)30 as protein binding motifs.
When added to growth media containing mammalian cells, these
compounds rapidly become incorporated into cellular plasma
membranes. The half-lives of these artificial receptors on the
surface of living cells, as detected with a fluorescent ligand (e.g.
t1/2(6) ∼ 20 h),28 are comparable to those of GPI-linked folate
receptors (t1/2 ∼ 24 h).31 Mammalian cells treated with these
synthetic receptors gain the capacity to endocytose normally
impermeable protein ligands, and these ligands are typically
delivered to late endosomes and lysosomes.27–30 Because of these
functional similarities between our synthetic receptors (Fig. 4)
and other internalizing cell surface receptors, we termed this
delivery approach “synthetic receptor targeting” (Fig. 5).28,30
The cellular uptake of ligands mediated by receptors derived
from N-alkyl-3b-cholesterylamines appears to mimic endocytic
cellular penetration mechanisms employed by certain protein
toxins and viruses.23 These mechanisms are highly complex at
Fig. 4 Structures of previously reported synthetic cell surface receptors derived from N-alkyl-3b-cholesterylamine. Ligands: antifluorescein IgG
(receptors 1 and 8), streptavidin (receptors 2 and 5), anti-hemagglutinin tag IgG (receptor 3), anti-flag tag IgG (receptor 4), and anti-dinitrophenyl
IgG (receptors 6 and 7).
Fig. 5 The synthetic receptor targeting approach for enhancing the cellular uptake of impermeable ligands. Living mammalian cells are treated
with synthetic mimics of cell surface receptors (R). These receptors become incorporated in cellular plasma membranes, enabling the cellular uptake
of cognate ligands such as macromolecular antibodies (IgG) bound to bacterial protein A (PrA) by synthetic receptor-mediated endocytosis. The
receptors in the center of the cell represent the population in intracellular endosomes in dynamic exchange with receptors on the cell surface.
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the molecular level and appear to involve clathrin-mediated en-
docytosis, raft-mediated endocytosis, or a combination thereof,
depending on the cell type. Sucrose density gradient ultracen-
trifugation analysis of cells treated with synthetic receptor 6 and
fluorescent anti-dinitrophenyl (anti-DNP) IgG ligand revealed
that this ligand co-fractionates with cholera toxin in a putative
low-density lipid raft fraction of the plasma membrane.28 These
and other results suggest significant similarities between the
initial steps of uptake of cholera toxin, mediated by ganglioside
GM1, and the uptake of ligands mediated by synthetic receptors
such as 1–8.
In the absence of a ligand, many N-alkyl-3b-cholesterylamine
derivatives rapidly and constitutively cycle between the cell
surface and endosomes. For example, receptor 8 makes a round
trip between these compartments in approximately 10 min.28
The fluorescent sphingolipid C6-NBD-sphingomyelin32 and
the macromolecular LDL receptor3 exhibit similar kinetics
of constitutive plasma membrane recycling.33 However, the
internalization of ligands such as anti-DNP IgG mediated by
receptor 6 is slower (t1/2 ∼ 95 min)28 than the uptake of LDL by
the LDL receptor (t1/2 < 10 min),3 possibly due to the ability of
the LDL receptor to interact directly or indirectly with clathrin
through its intracellular domain. Despite this slower rate of
ligand uptake, treatment of human Jurkat lymphocytes for 1 h
with synthetic receptor 6 (10 lM), followed by the washing of
cells to remove any unincorporated receptor, and the addition
of the ligand for an additional 4 h, enhances the endocytic
uptake of fluorescent anti-DNP IgG bound to bacterial Protein
A34 by over 200-fold with low toxicity.28 The effectiveness of
this delivery system appears to relate in part to the ability
of receptor 6 to dissociate from ligands in acidic endosomes
and return to the cell surface by plasma membrane recycling
for additional rounds of delivery. A simple model of synthetic
receptor-mediated endocytosis is shown in Fig. 6.
Cholesterol is a major component of both mammalian
plasma membranes and endosomes involved in plasma mem-
brane recycling.35 Hence endocytic recycling of N-alkyl-3b-
cholesterylamine derivatives is likely to relate to mimicry of
this critical membrane sterol. However, the appended linker
region and protein-binding headgroups of synthetic receptors
derived from this cholesterol mimic can substantially affect
subcellular trafficking and the localization on the cell surface
and on intracellular membranes. Studies of receptors 6 and
7 and related compounds revealed that insertion of b-alanine
amino acids into this linker region can substantially increase the
number of these receptors on the cell surface compared with the
number in intracellular endosomes.28 For example, fluorescence-
quenching experiments with receptor 7 (bearing two b-alanine
subunits in the linker region) revealed that after treatment of
cells for 1 h, 53% of this compound was localized on the plasma
membrane, with the other 47% residing in endosomes. Under
the same conditions, removal of one b-alanine from the linker
reduced the cell surface population to 23%, and removal of both
b-alanines resulted in only 3% of the compound on the plasma
membrane, with the remainder in endosomes. Not surprisingly,
the percentage of receptors on the cell surface is highly correlated
with the efficiency of these compounds as mediators of ligand
uptake.28
The secondary amine of N-alkyl-3b-cholesterylamines is
protonated at physiological pH. This protonation stabilizes as-
sociation of the membrane anchor with the cell surface and may
contribute to efficient plasma membrane recycling. In contrast,
structurally related N-acyl derivatives (amide analogues) of 3b-
cholesterylamine often differ significantly in membrane traffick-
ing and generally are significantly less effective as synthetic re-
ceptors. Unlike 3b-amines that cycle between the cell surface and
endosomes, analogous 3b-amides, particularly those bearing
uncharged headgroups, tend to localize at internal membranes of
the Golgi complex and nuclear membrane of living cells.28 Fluo-
rescent esters of cholesterol similarly localize at these intracellu-
lar membranes,36 and N-acyl derivatives of 3b-cholesterylamines
presumably mimic the trafficking of natural cholesteryl esters.
Although the molecular determinants governing the localization
of synthetic receptors on specific membranes of living cells are
not yet fully defined, interactions of the membrane anchor and
the headgroup with neighboring lipids, proteins, and carbohy-
drates involved in membrane trafficking is likely to determine
the ultimate subcellular destination of these compounds.
Membrane anchors derived from N-alkyl-3b-cholesteryl-
amine can insert into cellular plasma membranes of living
mammalian cells and rapidly cycle between the cell surface and
endosomes. This plasma membrane recycling enables derivatives
linked to motifs that bind proteins and other impermeable
ligands to function as artificial cell surface receptors. The linker
region of these compounds can be tuned to maximize the
fraction of receptor on the cell surface and optimize ligand
uptake by these compounds. Artificial cell surface receptors
constructed in this way provide unique probes of molecular
recognition on cell surfaces and novel agents for the delivery
of myriad compounds into mammalian cells.
Other related approaches for the endocytic delivery
of impermeable compounds
Several cell surface engineering approaches have been used
to enhance the cellular uptake of impermeable molecules.37
Fig. 6 A simple model of synthetic receptor-mediated endocytosis. Synthetic receptors embedded in the cellular plasma membrane rapidly cycle
between the cell surface and intracellular endosomes. Binding of ligand (IgG) results in association with lipid rafts and uptake of the complex by
endocytosis. Dissociation in endosomes frees the receptor to return to the cell surface. The protein ligand is sorted to late endosomes and lysosomes.
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One strategy termed “cellular painting” incorporates proteins
linked to glycosylphosphatidylinositol (GPI) lipid anchors into
cellular plasma membranes.38–42 Cellular painting has primar-
ily been used to study cellular signaling, plasma membrane
organization, and immunological responses to modified cell
surfaces. However, GPI-linked proteins undergo raft-mediated
endocytosis43 and can be used to deliver molecules into cells. For
example, Jurkat lymphocytes treated with a GPI-linked variant
of an immunoglobulin Fc receptor (FccRIII) will endocytose
an antibody directed against this receptor.44 Structurally related
artificial cell surface receptors have also been construced from
single-chain antibodies covalently linked to lipids.45 In an-
other related approach, polyethylene glycol (PEG)-linked lipids
covalently46 or noncovalently47 attached to proteins have been
used to immobilize macromolecules on cell surfaces. These PEG
derivatives primarily anchor proteins on the outer leaflet of the
plasma membrane, but, in certain cases, they can also promote
the endocytosis of protein ligands.
The installation of abiotic functional groups into carbohy-
drates on cell surfaces by metabolic oligosaccaride engineering is
another approach to add prosthetic molecules to living cells.48,49
By feeding cells unnatural sugars, cellular metabolism can be
harnessed to display bioorthogonal functional groups such as
ketones and azides on cell surfaces. Reaction of these ketones
with hydrazine derivatives to yield hydrazones,50 as well as the
reaction of azides with modified phosphines in the Staudinger
ligation,51 can immobilize molecules on the cell surface and
promote delivery of proteins such as the toxin ricin.50 This
approach has been shown to function in living animals.52
Cell penetrating peptides and proteins (CPPs) represent
another approach widely used to deliver molecules into cells
both in vitro and in vivo.53–58 CPPs comprise basic segments
of HIV Tat and other proteins, polyarginine peptides, and
related cationic oligomers. These delivery agents are generally
fused or otherwise covalently linked to impermeable proteins
and drugs to promote cellular uptake. Mechanisms of cellular
uptake of CPPs are thought to be either endocytic or non-
endocytic depending on the CPP, the size of its cargo, and the
cell type. Some CPPs, particularly linked to a large cargo such as
proteins,59 undergo endocytosis mediated by binding to anionic
cell surface components such as extracellular heparin sulfates.60
Future directions
Modern techniques of molecular biology provide powerful
genetic tools to endow cells with new molecules capable of
unique functions. For example, cells transfected with genes
encoding artificial cell surface receptors that bind the imaging
agent technetium-99 enable tracking of cells in vivo.61 In contrast,
the use of synthetic molecules as cellular prostheses, adding
new functions such as endocytosis, is much less well developed.
However, this chemical approach for controlling biology has the
potential to vastly increase the diversity of molecules that can
be interfaced with cells, tissues, and organisms.
As a chemical approach to endow living cells with the capacity
to internalize specific molecules, artificial cell surface receptors
can be constructed from the membrane anchor N-alkyl-3b-
cholesterylamine. These compounds can exhibit long cellular
half-lives, rapidly cycle between the cell surface and intracel-
lular endosomes, and mimic the internalization functions of
many mammalian cell surface receptors. Because N-alkyl-3b-
cholesterylamine derivatives appear to mimic aspects of the sub-
cellular trafficking of cholesterol, these compounds may provide
useful probes of cholesterol-rich membrane subdomains and as-
sociated mechanisms that regulate the segregation, localization,
and sorting of membrane-bound biomolecules. Synthetic cell
surface receptors may also provide novel approaches for cellular
targeting and drug delivery. Cellular targeting applications may
be facilitated by the structural similarity of these compounds to
cholesterol, which may allow packaging of synthetic receptors in
LDL or other cholesterol-carrying particles for selective delivery
to tumor cells.5,62 Because targets of many drugs are intracellular,
synthetic receptors that promote the endocytosis of drugs might
provide novel tools for drug delivery. This approach may require
the development of methods to disrupt endosomal membranes
to efficiently access the cellular cytoplasm and nucleus. However,
synthetic cell surface receptors that irreversibly deliver proteins
into degratory lysosomes might also be useful for the removal of
undesirable proteins from the extracellular environment. With
appropriately designed synthetic receptors, this ligand depletion
approach could potentially be used to target autoreactive
antibodies, tumor-promoting growth factors, or inflammatory
cytokines involved in numerous diseases.
Synthetic receptors derived from N-alkyl-3b-
cholesterylamines most closely mimic GPI-linked receptors and
glycolipids that are anchored to the outer leaflet of the cellular
plasma membrane. However, many cell surface receptors are
transmembrane proteins that engage both extracellular ligands
and intracellular proteins involved in signaling and endocytosis.
To mimic these receptors, the development of compounds that
span the plasma membrane to access intracellular proteins
could provide powerful new tools for controlling myriad
cellular functions including cellular proliferation and apoptosis.
Previously reported steroid dimers that span lipid bilayers of
liposomes and mimic aspects of cellular signaling63 provide
inspiration for the design of transmembrane compounds that
might function on living cells. The creation of prosthetic
molecules that seamlessly access the molecular machinery of
living cells represents an exciting new frontier in the fields of
bioorganic chemistry and chemical biology.
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